Pertussis toxin and adenylate cyclase toxin: Key virulence factors of Bordetella pertussis and cell biology tools

Future Microbiology

Volumn 5, Issue 3, 2010, Pages 455-469

  Carbonetti, Nicholas H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adenylate cyclase toxin; Bordetella pertussis; Immunosuppression; Pertussis toxin; Respiratory infection; Whooping cough

Indexed keywords

ADENYLATE CYCLASE TOXIN; CHEMOKINE RECEPTOR CXCR4; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; LIPOPOLYSACCHARIDE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TOLL LIKE RECEPTOR 4;

ACYLATION; ADAPTIVE IMMUNITY; ADENOSINE DIPHOSPHATE RIBOSYLATION; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; CARBOXY TERMINAL SEQUENCE; CELL ACTIVITY; CELL TRANSPORT; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DNA SEQUENCE; ENZYME ACTIVITY; HEMOLYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LUNG ALVEOLUS MACROPHAGE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PERTUSSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE ACTIVATION; TOXIN STRUCTURE; UBIQUITINATION;

ADENYLATE CYCLASE TOXIN; BORDETELLA PERTUSSIS; CYTOLOGICAL TECHNIQUES; HUMANS; PERTUSSIS TOXIN; VIRULENCE FACTORS, BORDETELLA;

BACTERIA (MICROORGANISMS); BORDETELLA PERTUSSIS; MAMMALIA;

EID: 77949345512     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.133     Document Type: Review

References (135)

1. Mattoo S, Cherry JD: Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18, 326-382 (2005).
2. Wood N, McIntyre P: Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr. Respir. Rev. 9, 201-211 (2008).
3. Carbonetti NH: Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease. Curr. Opin. Pharmacol. 7, 272-278 (2007).
4. Paddock CD, Sanden GN, Cherry JD et al.: Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin. Infect. Dis. 47, 328-338 (2008).
5. He Q, Mertsola J: Factors contributing to pertussis resurgence. Future Microbiol. 3, 329-339 (2008).
6. Mills KH: Immunity to Bordetella pertussis. Microbes Infect. 3, 655-677 (2001).
7. Verma A, Burns DL: Requirements for assembly of PtlH with the pertussis toxin transporter apparatus of Bordetella pertussis. Infect. Immun. 75, 2297-2306 (2007).
8. Verma A, Cheung AM, Burns DL: Stabilization of the pertussis toxin secretion apparatus by the C terminus of PtlD. J. Bacteriol. 190, 7285-7290 (2008).
9. Witvliet MH, Burns DL, Brennan MJ, Poolman JT, Manclark CR: Binding of pertussis toxin to eucaryotic cells and glycoproteins. Infect. Immun. 57, 3324-3330 (1989).
10. Wong WS, Rosoff PM: Pharmacology of pertussis toxin B-oligomer. Can. J. Physiol. Pharmacol. 74, 559-564 (1996).
11. Saukkonen K, Burnette WN, Mar VL, Masure HR, Tuomanen EI: Pertussis toxin has eukaryotic-like carbohydrate recognition domains. Proc. Natl Acad. Sci. USA 89, 118-122 (1992).
12. Stein PE, Boodhoo A, Armstrong GD et al.: Structure of a pertussis toxin-sugar complex as a model for receptor binding. Nat. Struct. Biol. 1, 591-596 (1994).
13. Katada T, Tamura M, Ui M: The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein. Arch. Biochem. Biophys. 224, 290-298 (1983).
14. Moss J, Stanley SJ, Burns DL et al.: Activation by thiol of the latent NAD glycohydrolase and ADP-ribosyltransferase activities of Bordetella pertussis toxin (islet-activating protein). J. Biol. Chem. 258, 11879-11882 (1983).
15. Burns DL, Manclark CR: Adenine nucleotides promote dissociation of pertussis toxin subunits. J. Biol. Chem. 261, 4324-4327 (1986).
16. Hazes B, Boodhoo A, Cockle SA, Read RJ: Crystal structure of the pertussis toxin-ATP complex: a molecular sensor. J. Mol. Biol. 258, 661-671 (1996).
17. Stein PE, Boodhoo A, Armstrong GD, Cockle SA, Klein MH, Read RJ: The crystal structure of pertussis toxin. Structure 2, 45-57 (1994).
18. Pierce C, Klein N, Peters M: Is leukocytosis a predictor of mortality in severe pertussis infection? Intensive Care Med. 26, 1512-1514 (2000).
19. Mikelova LK, Halperin SA, Scheifele D et al.: Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J. Pediatr. 143, 576-581 (2003).
20. Trollfors B, Taranger J, Lagergard T et al.: A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333, 1045-1050 (1995).
21. Plaut RD, Carbonetti NH: Retrograde transport of pertussis toxin in the mammalian cell. Cell. Microbiol. 10, 1130-1139 (2008).
22. Vembar SS, Brodsky JL: One step at a time: endoplasmic reticulum-associated degradation. Nat. Rev. Mol. Cell. Biol. 9, 944-957 (2008).
23. Worthington ZE, Carbonetti NH: Evading the proteasome: absence of lysine residues contributes to pertussis toxin activity by evasion of proteasome degradation. Infect. Immun. 75, 2946-2953 (2007).
24. Pande AH, Moe D, Jamnadas M, Tatulian SA, Teter K: The pertussis toxin S1 subunit is a thermally unstable protein susceptible to degradation by the 20S proteasome. Biochemistry 45, 13734-13740 (2006).
25. Munoz JJ, Arai H, Bergman RK, Sadowski PL: Biological activities of crystalline pertussigen from Bordetella pertussis. Infect. Immun. 33, 820-826 (1981).
26. Goodwin MS, Weiss AA: Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice. Infect. Immun. 58, 3445-3447 (1990).
27. Carbonetti NH, Artamonova GV, Andreasen C, Bushar N: Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory tract. Infect. Immun. 73, 2698-2703 (2005).
28. Carbonetti NH, Artamonova GV, Mays RM, Worthington ZE: Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect. Immun. 71, 6358-6366 (2003).
29. Carbonetti NH, Artamonova GV, Van Rooijen N, Ayala VI: Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infect. Immun. 75, 1713-1720 (2007).
30. Lattin J, Zidar DA, Schroder K, Kellie S, Hume DA, Sweet MJ: G-protein-coupled receptor expression, function, and signaling in macrophages. J. Leukoc. Biol. 82, 16-32 (2007).
31. Andreasen C, Carbonetti NH: Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice. Infect. Immun. 76, 5139-5148 (2008).
32. Kirimanjeswara GS, Agosto LM, Kennett MJ, Bjornstad ON, Harvill ET: Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J. Clin. Invest. 115, 3594-3601 (2005).
33. Reutershan J, Basit A, Galkina EV, Ley K: Sequential recruitment of neutrophils into lung and bronchoalveolar lavage fuid in LPS-induced acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L807-L815 (2005).
34. Pero RS, Borchers MT, Spicher K et al.: Gai2-mediated signaling events in the endothelium are involved in controlling leukocyte extravasation. Proc. Natl Acad. Sci. USA 104, 4371-4376 (2007).
35. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH: TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177, 7980-7989 (2006).
36. Ross PJ, Lavelle EC, Mills KH, Boyd AP: Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells. Infect. Immun. 72, 1568-1579 (2004).
37. Mann PB, Wolfe D, Latz E, Golenbock D, Preston A, Harvill ET: Comparative toll-like receptor 4-mediated innate host defense to Bordetella infection. Infect. Immun. 73, 8144-8152 (2005).
38. Banus S, Stenger RM, Gremmer ER et al.: The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol. 9, 21 (2008).
39. Fedele G, Nasso M, Spensieri F et al.: Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis differently modulate human dendritic cell functions resulting in divergent prevalence of Th17-polarized responses. J. Immunol. 181, 208-216 (2008).
40. Lentschat A, Karahashi H, Michelsen KS et al.: Mastoparan, a G protein agonist peptide, differentially modulates TLR4-and TLR2-mediated signaling in human endothelial cells and murine macrophages. J. Immunol. 174, 4252-4261 (2005).
41. Fan H, Peck OM, Tempel GE, Halushka PV, Cook JA: Toll-like receptor 4 coupled GI protein signaling pathways regulate extracellular signal-regulated kinase phosphorylation and AP-1 activation independent of NFkB activation. Shock 22, 57-62 (2004).
42. Andreasen C, Carbonetti NH: Role of neutrophils in response to Bordetella pertussis infection in mice. Infect. Immun. 7 7, 1182-1188 (2009).
43. Andreasen C, Powell D, Carbonetti NH: Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS ONE 4, E7079 (2009).
44. Wolfe DN, Mann PB, Buboltz AM, Harvill ET: Delayed role of tumor necrosis factor-a in overcoming the effects of pertussis toxin. J. Infect. Dis. 196, 1228-1236 (2007).
45. Carbonetti NH, Artamonova GV, Andreasen C, Dudley E, Mays RM, Worthington ZE: Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identifcation of an immunodominant lipoprotein. Infect. Immun. 72, 3350-3358 (2004).
46. Shumilla JA, Lacaille V, Hornell TM et al.: Bordetella pertussis infection of primary human monocytes alters HLA-DR expression. Infect. Immun. 72, 1450-1462 (2004).
47. Martino A, Volpe E, Auricchio G, Colizzi V, Baldini PM: Infuence of pertussis toxin on CD1a isoform expression in human dendritic cells. J. Clin. Immunol. 26, 153-159 (2006).
48. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N: First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 27(43), 6034-6041 (2009).
49. Mooi FR, van Loo IHM, van Gent M et al.: Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg. Infect. Dis. 15, 1206-1213 (2009).
50. Robbins JB, Schneerson R, Keith JM, Miller MA, Kubler-Kielb J, Trollfors B: Pertussis vaccine: a critique. Pediatr. Infect. Dis. J. 28, 237-241 (2009).
51. Pizza M, Covacci A, Bartoloni A et al.: Mutants of pertussis toxin suitable for vaccine development. Science 246, 497-500 (1989).
52. Alfano M, Schmidtmayerova H, Amella CA, Pushkarsky T, Bukrinsky M: The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains. J. Exp. Med. 190, 597-605 (1999).
53. Rizzi C, Alfano M, Bugatti A, Camozzi M, Poli G, Rusnati M: Inhibition of intra-and extra-cellular Tat function and HIV expression by pertussis toxin B-oligomer. Eur. J. Immunol. 34, 530-536 (2004).
54. Zocchi MR, Contini P, Alfano M, Poggi A: Pertussis toxin (PTX) B subunit and the nontoxic PTX mutant PT9K/129G inhibit Tat-induced TGF-b production by NK cells and TGF-b-mediated NK cell apoptosis. J. Immunol. 174, 6054-6061 (2005).
55. Poggi A, Zocchi MR: HIV-1 Tat triggers TGF-b production and NK cell apoptosis that is prevented by pertussis toxin B. Clin. Dev. Immunol. 13, 369-372 (2006).
56. Jajoo S, Mukherjea D, Brewer GJ, Ramkumar V: Pertussis toxin B-oligomer suppresses human immunodefciency virus-1 Tat-induced neuronal apoptosis through feedback inhibition of phospholipase C-b by protein kinase C. Neuroscience 151, 525-532 (2008).
57. Rizzi C, Crippa MP, Jeeninga RE et al.: Pertussis toxin B-oligomer suppresses IL-6 induced HIV-1 and chemokine expression in chronically infected U1 cells via inhibition of activator protein 1. J. Immunol. 176, 999-1006 (2006).
58. Hu Q, Younson J, Griffn GE, Kelly C, Shattock RJ: Pertussis toxin and its binding unit inhibit HIV-1 infection of human cervical tissue and macrophages involving a CD14 pathway. J. Infect. Dis. 194, 1547-1556 (2006).
59. Lapenta C, Spada M, Santini SM et al.: Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice. Int. Immunol. 17, 469-475 (2005).
60. Alfano M, Grivel JC, Ghezzi S et al.: Pertussis toxin B-oligomer dissociates T cell activation and HIV replication in CD4 T cells released from infected lymphoid tissue. AIDS 19, 1007-1014 (2005).
61. Ryan M, McCarthy L, Rappuoli R, Mahon BP, Mills KH: Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int. Immunol. 10, 651-662 (1998).
62. Wang ZY, Yang D, Chen Q et al.: Induction of dendritic cell maturation by pertussis toxin and its B subunit differentially initiate Toll-like receptor 4-dependent signal transduction pathways. Exp. Hematol. 34, 1115-1124 (2006).
63. Nasso M, Fedele G, Spensieri F et al.: Genetically detoxifed pertussis toxin induces Th1/Th17 immune response through MAPKs and IL-10-dependent mechanisms. J. Immunol. 183, 1892-1899 (2009).
64. Schneider OD, Weiss AA, Miller WE: Pertussis toxin utilizes proximal components of the T-cell receptor complex to initiate signal transduction events in T cells. Infect. Immun. 75, 4040-4049 (2007).
65. Schneider OD, Weiss AA, Miller WE: Pertussis toxin signals through the TCR to initiate cross-desensitization of the chemokine receptor CXCR4. J. Immunol. 182, 5730-5739 (2009).
66. Munoz JJ, Bernard CC, Mackay IR: Elicitation of experimental allergic encephalomyelitis (EAE) in mice with the aid of pertussigen. Cell. Immunol. 83, 92-100 (1984).
67. Kugler S, Bocker K, Heusipp G, Greune L, Kim KS, Schmidt MA: Pertussis toxin transiently affects barrier integrity, organelle organization and transmigration of monocytes in a human brain microvascular endothelial cell barrier model. Cell. Microbiol. 9, 619-632 (2007).
68. Kerfoot SM, Long EM, Hickey MJ et al.: TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J. Immunol. 173, 7070-7077 (2004).
69. + T regulatory cells. Eur. J. Immunol. 36, 671-680 (2006).
70. + regulatory T cells. J. Immunol. 177, 1552-1560 (2006).
71. Low cells in vivo. J. Immunol. 177, 4384-4390 (2006).
72. Chen X, Howard OM, Oppenheim JJ: Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J. Immunol. 178, 6123-6129 (2007).
73. Komiyama Y, Nakae S, Matsuki T et al.: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177, 566-573 (2006).
74. Millward JM, Caruso M, Campbell IL, Gauldie J, Owens T: IFN-g-induced chemokines synergize with pertussis toxin to promote T cell entry to the central nervous system. J. Immunol. 178, 8175-8182 (2007).
75. Fujimoto C, Shi G, Gery I: Microbial products trigger autoimmune ocular infammation. Ophthalmic Res. 40, 193-199 (2008).
76. Fujimoto C, Yu CR, Shi G et al.: Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production. J. Immunol. 177, 6896-6903 (2006).
77. Vojtova J, Kamanova J, Sebo P: Bordetella adenylate cyclase toxin: a swift saboteur of host defense. Curr. Opin. Microbiol. 9, 69-75 (2006).
78. Gray MC, Donato GM, Jones FR, Kim T, Hewlett EL: Newly secreted adenylate cyclase toxin is responsible for intoxication of target cells by Bordetella pertussis. Mol. Microbiol. 53, 1709-1719 (2004).
79. Guermonprez P, Khelef N, Blouin E et al.: The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the a(M) b(2) integrin (CD11b/CD18). J. Exp. Med. 193, 1035-1044 (2001).
80. Morova J, Osicka R, Masin J, Sebo P: RTX cytotoxins recognize b2 integrin receptors through N-linked oligosaccharides. Proc. Natl Acad. Sci. USA 105, 5355-5360 (2008).
81. Guo Q, Shen Y, Lee YS, Gibbs CS, Mrksich M, Tang WJ: Structural basis for the interaction of Bordetella pertussis adenylyl cyclase toxin with calmodulin. EMBO J. 24, 3190-3201 (2005).
82. Guo Q, Jureller JE, Warren JT, Solomaha E, Florian J, Tang WJ: Protein-protein docking and analysis reveal that two homologous bacterial adenylyl cyclase toxins interact with calmodulin differently. J. Biol. Chem. 283, 23836-23845 (2008).
83. El-Azami-El-Idrissi M, Bauche C, Loucka J et al.: Interaction of Bordetella pertussis adenylate cyclase with CD11b/CD18: role of toxin acylation and identifcation of the main integrin interaction domain. J. Biol. Chem. 278, 38514-38521 (2003).
84. Masin J, Basler M, Knapp O et al.: Acylation of lysine 860 allows tight binding and cytotoxicity of Bordetella adenylate cyclase on CD11b-expressing cells. Biochemistry 44, 12759-12766 (2005).
85. Lee SJ, Gray MC, Zu K, Hewlett EL: Oligomeric behavior of Bordetella pertussis adenylate cyclase toxin in solution. Arch. Biochem. Biophys. 438, 80-87 (2005).
86. Vojtova-Vodolanova J, Basler M, Osicka R et al.: Oligomerization is involved in pore formation by Bordetella adenylate cyclase toxin. Faseb. J. 23, 2831-2843 (2009).
87. Basler M, Knapp O, Masin J et al.: Segments crucial for membrane translocation and pore-forming activity of Bordetella adenylate cyclase toxin. J. Biol. Chem. 282, 12419-12429 (2007).
88. Powthongchin B, Angsuthanasombat C: Effects on haemolytic activity of single proline substitutions in the Bordetella pertussis CyaA pore-forming fragment. Arch. Microbiol. 191, 1-9 (2009).
89. Knapp O, Maier E, Masin J, Sebo P, Benz R: Pore formation by the Bordetella adenylate cyclase toxin in lipid bilayer membranes: role of voltage and pH. Biochim. Biophys. Acta 1778, 260-269 (2008).
90. Lilie H, Haehnel W, Rudolph R, Baumann U: Folding of a synthetic parallel b-roll protein. FEBS Lett. 470, 173-177 (2000).
91. Bauche C, Chenal A, Knapp O et al.: Structural and functional characterization of an essential RTX subdomain of Bordetella pertussis adenylate cyclase toxin. J. Biol. Chem. 281, 16914-16926 (2006).
92. Chenal A, Guijarro JI, Raynal B, Delepierre M, Ladant D: RTX calcium binding motifs are intrinsically disordered in the absence of calcium: implication for protein secretion. J. Biol. Chem. 284, 1781-1789 (2009).
93. Hewlett EL, Donato GM, Gray MC: Macrophage cytotoxicity produced by adenylate cyclase toxin from Bordetella pertussis: more than just making cyclic AMP! Mol. Microbiol. 59, 447-459 (2006).
94. Basler M, Masin J, Osicka R, Sebo P: Pore-forming and enzymatic activities of Bordetella pertussis adenylate cyclase toxin synergize in promoting lysis of monocytes. Infect. Immun. 74, 2207-2214 (2006).
95. + monocytes independently of the catalytic and hemolytic activities. J. Biol. Chem. 282, 2808-2820 (2007).
96. Vojtova J, Kofronova O, Sebo P, Benada O: Bordetella adenylate cyclase toxin induces a cascade of morphological changes of sheep erythrocytes and localizes into clusters in erythrocyte membranes. Microsc. Res. Tech. 69, 119-129 (2006).
97. Ohnishi H, Miyake M, Kamitani S, Horiguchi Y: The morphological changes in cultured cells caused by Bordetella pertussis adenylate cyclase toxin. FEMS Microbiol. Lett. 279, 174-179 (2008).
98. Kamanova J, Kofronova O, Masin J et al.: Adenylate cyclase toxin subverts phagocyte function by RhoA inhibition and unproductive ruffing. J. Immunol. 181, 5587-5597 (2008).
99. Johansson D, Bergstrom P, Henriksson R et al.: Adenylate cyclase toxin from Bordetella pertussis enhances cisplatin-induced apoptosis to lung cancer cells in vitro. Oncol. Res. 15, 423-430 (2006).
100. Cheung GY, Kelly SM, Jess TJ et al.: Functional and structural studies on different forms of the adenylate cyclase toxin of Bordetella pertussis. Microb. Pathog. 46, 36-42 (2009).
101. Confer D, Eaton J: Phagocyte impotence caused by an invasive bacterial adenylate cyclase. Science 217, 948-950 (1982).
102. Gross MK, Au DC, Smith AL, Storm DR: Targeted mutations that ablate either the adenylate cyclase or hemolysin function of the bifunctional cyaA toxin of Bordetella pertussis abolish virulence. Proc. Natl Acad. Sci. USA 89, 4898-4902 (1992).
103. Khelef N, Sakamoto H, Guiso N: Both adenylate cyclase and hemolytic activities are required by Bordetella pertussis to initiate infection. Microb. Pathog. 12, 227-235 (1992).
104. Gueirard P, Druilhe A, Pretolani M, Guiso N: Role of adenylate cyclase-hemolysin in alveolar macrophage apoptosis during Bordetella pertussis infection in vivo. Infect. Immun. 66, 1718-1725 (1998).
105. Khelef N, Guiso N: Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase-hemolysin. FEMS Microbiol. Lett. 134, 27-32 (1995).
106. Khelef N, Zychlinsky A, Guiso N: Bordetella pertussis induces apoptosis in macrophages: role of adenylate cyclase-hemolysin. Infect. Immun. 61, 4064-4071 (1993).
107. Mobberley-Schuman PS, Weiss AA: Infuence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils. Infect. Immun. 73, 7317-7323 (2005).
108. Veal-Carr WL, Stibitz S: Demonstration of differential virulence gene promoter activation in vivo in Bordetella pertussis using RIVET. Mol. Microbiol. 55, 788-798 (2005).
109. Boyd AP, Ross PJ, Conroy H, Mahon N, Lavelle EC, Mills KH: Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death. J. Immunol. 175, 730-738 (2005).
110. Skinner JA, Reissinger A, Shen H, Yuk MH: Bordetella type III secretion and adenylate cyclase toxin synergize to drive dendritic cells into a semimature state. J. Immunol. 173, 1934-1940 (2004).
111. Spensieri F, Fedele G, Fazio C et al.: Bordetella pertussis inhibition of interleukin-12 (IL-12) p70 in human monocyte-derived dendritic cells blocks IL-12 p35 through adenylate cyclase toxin-dependent cyclic AMP induction. Infect. Immun. 74, 2831-2838 (2006).
112. Hickey FB, Brereton CF, Mills KH: Adenylate cycalse toxin of Bordetella pertussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells. J. Leukoc. Biol. 84, 234-243 (2008).
113. Paccani SR, Dal Molin F, Benagiano M et al.: Suppression of T-lymphocyte activation and chemotaxis by the adenylate cyclase toxin of Bordetella pertussis. Infect. Immun. 76, 2822-2832 (2008).
114. Rossi Paccani S, Benagiano M, Capitani N et al.: The adenylate cyclase toxins of Bacillus anthracis and Bordetella pertussis promote Th2 cell development by shaping T cell antigen receptor signaling. PLoS Pathog. 5, e1000325 (2009).
115. Perkins DJ, Gray MC, Hewlett EL, Vogel SN: Bordetella pertussis adenylate cyclase toxin (ACT) induces cyclooxygenase-2 (COX-2) in murine macrophages and is facilitated by ACT interaction with CD11b/CD18 (Mac-1). Mol. Microbiol. 66, 1003-1015 (2007).
116. Cheung GY, Dickinson P, Sing G et al.: Transcriptional responses of murine macrophages to the adenylate cyclase toxin of Bordetella pertussis. Microb. Pathog. 44, 61-70 (2008).
117. + T cell epitopes and in vivo Th1-polarized T cell priming. J. Immunol. 173, 6089-6097 (2004).
118. Simsova M, Sebo P, Leclerc C: The adenylate cyclase toxin from Bordetella pertussis-a novel promising vehicle for antigen delivery to dendritic cells. Int. J. Med. Microbiol. 293, 571-576 (2004).
119. + T-cell epitopes to dendritic cells and elicits CTL in vivo. Vaccine 23, 604-614 (2004).
120. Mascarell L, Bauche C, Fayolle C et al.: Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specifc Th1 responses and high affnity neutralizing antibodies in non human primates. Vaccine 24, 3490-3499 (2006).
121. + T-cell responses following delivery of human immunodefciency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. J. Virol. 79, 9872-9884 (2005).
122. Tartz S, Russmann H, Kamanova J et al.: Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid. Vaccine 26, 5935-5943 (2008).
123. Connell TG, Shey MS, Seldon R et al.: Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specifc T cells in human immunodefciency virus-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector. Clin. Vaccine Immunol. 14, 847-854 (2007).
124. Wilkinson KA, Simsova M, Scholvinck E et al.: Effcient ex vivo stimulation of Mycobacterium tuberculosis-specifc T cells by genetically detoxifed Bordetella pertussis adenylate cyclase antigen toxoids. Infect. Immun. 73, 2991-2998 (2005).
125. Dautin N, Karimova G, Ladant D: Bordetella pertussis adenylate cyclase toxin: a versatile screening tool. Toxicon 40, 1383-1387 (2002).
126. Geddes K, Worley M, Niemann G, Heffron F: Identifcation of new secreted effectors in Salmonella enterica serovar Typhimurium. Infect. Immun. 73, 6260-6271 (2005).
127. Gendlina I, Held KG, Bartra SS et al.: Identifcation and type III-dependent secretion of the Yersinia pestis insecticidal-like proteins. Mol. Microbiol. 64, 1214-1227 (2007).
128. Furutani A, Takaoka M, Sanada H et al.: Identifcation of novel type III secretion effectors in Xanthomonas oryzae pv. oryzae. Mol. Plant Microbe Interact. 22, 96-106 (2009).
129. Miyake M, Sakane S, Kobayashi C et al.: A colorimetric assay for studying effector secretion through the bacterial type III secretion system. FEMS Microbiol. Lett. 278, 36-42 (2008).
130. Karimova G, Robichon C, Ladant D: Characterization of YmgF, a 72-residue inner membrane protein that associates with the Escherichia coli cell division machinery. J. Bacteriol. 191, 333-346 (2009).
131. Real SM, Marzese DM, Gomez LC, Mayorga LS, Roque M: Development of a premature stop codon-detection method based on a bacterial two-hybrid system. BMC Biotechnol. 6, 38 (2006).
132. Guiso N, Szatanik M, Rocancourt M: Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization. Microb. Pathog. 11, 423-431 (1991).
133. Weingart CL, Mobberley-Schuman PS, Hewlett EL, Gray MC, Weiss AA: Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils. Infect. Immun. 68, 7152-7155 (2000).
134. Cheung GY, Xing D, Prior S, Corbel MJ, Parton R, Coote JG: Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model. Infect. Immun. 74, 6797-6805 (2006).
135. Prior S, Fleck RA, Gillett ML et al.: Evaluation of adenyl cyclase toxin constructs from Bordetella pertussis as candidate vaccine components in an in vitro model of complement-dependent intraphagocytic killing. Vaccine 24, 4794-4803 (2006).